Mira Pharmaceuticals advances MIRA-55 toward IND-enabling studies after completing exploratory tox dosing in rats, dogs

• Mira Pharmaceuticals moved two preclinical oral candidates, MIRA-55 for chronic inflammatory pain and SKNY-1 for obesity and addiction-related disorders, toward IND-enabling studies.
• No clinical results were presented; exploratory 7-day repeat-dose safety studies in rats and dogs completed dosing and necropsy, with analyses still underway.
• Early readouts are intended to support tolerability assessment and dose selection for upcoming GLP IND-enabling toxicology, not to establish efficacy.
• Formulation, manufacturing, and CMC work continued to prepare for GLP toxicology and subsequent clinical development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607300800PRIMZONEFULLFEED9800651) on July 30, 2026, and is solely responsible for the information contained therein.